Table 1 |
|||
|
Patient demographics and tumor characteristics |
|||
|
All Disease |
|||
|
|
|||
|
APBI |
WBI |
P value |
|
|
Patients |
202 |
94 |
|
|
Months Follow-up |
64.3 |
64.1 |
0.422 |
|
(Range) |
(2.2-96.6) |
(4.4-98.4) |
|
|
Median Age |
60.0 |
56.9 |
0.087 |
|
(Range) |
(34.7-84.3) |
(33.0-83.2) |
|
|
Race |
< 0.001* |
||
|
Caucasian |
169 (83.7%) |
52 (55.3%) |
|
|
Black |
31 (15.4%) |
42 (44.7%) |
|
|
Other |
2 (1.0%) |
0 (0%) |
|
|
Anatomy |
|||
|
Side |
0.803 |
||
|
Right |
97 (48.0%) |
47 (50.0%) |
|
|
Left |
105 (52.0%) |
47 (50.0%) |
|
|
Quadrant |
|||
|
UOQ |
88 (43.6%) |
64 (68.1%) |
< 0.001* |
|
UIQ |
53 (26.2%) |
17 (18.1%) |
|
|
LIQ |
29 (14.4%) |
5 (5.3%) |
|
|
LOQ |
32 (15.8%) |
8 (8.5%) |
|
|
Grade |
0.207 |
||
|
DCIS |
40 (19.8%) |
18 (19.1%) |
|
|
I |
78 (38.6%) |
25 (26.6%) |
|
|
II |
55 (27.2%) |
27 (28.7%) |
|
|
III |
29 (14.4%) |
20 (21.3%) |
|
|
Unknown |
0 (0%) |
4 (4.3%) |
|
|
Stage |
|||
|
Tis |
40 (19.8%) |
18 (19.1%) |
|
|
T1mic |
3 (1.5%) |
4 (4.3%) |
|
|
T1a |
23 (11.4%) |
7 (7.4%) |
|
|
T1b |
67 (33.2%) |
29 (30.9%) |
|
|
T1c |
54 (26.7%) |
31 (33.0%) |
|
|
T1 |
147 (72.8%) |
71 (75.5%) |
|
|
T2 |
15 (7.4%) |
5 (5.3%) |
|
|
Histology |
0.092 |
||
|
DCIS |
40 (19.8%) |
18 (19.1%) |
|
|
Invasive Ductal |
141 (69.8%) |
60 (63.8%) |
|
|
Invasive Lobular |
8 (4.0%) |
11 (11.7%) |
|
|
Invasive Tubular |
7 (3.5%) |
1 (1.1%) |
|
|
Invasive Mucinous |
5 (2.5%) |
2 (2.1%) |
|
|
Invasive Papillary |
1 (0.5%) |
2 (2.1%) |
|
|
Estrogen Receptor |
0.464 |
||
|
ER + |
167 (82.7%) |
71 (71.6%) |
|
|
ER - |
26 (12.9%) |
15 (16.0%) |
|
|
ER Unknown |
9 (4.5%) |
8 (8.5%) |
|
|
Progesterone Receptor |
0.489 |
||
|
PR + |
134 (66.3%) |
56 (59.6%) |
|
|
PR - |
59 (29.2%) |
30 (31.9%) |
|
|
PR Unknown |
9 (4.5%) |
8 (8.5%) |
|
|
Her-2/Neu (Invasive Only) |
0.350 |
||
|
Overexpressed |
14 (6.9%) |
9 (4.5%) |
|
|
Not Overexpressed |
147 (72.8%) |
62 (66.0%) |
|
|
Unknown |
41 (20.3%) |
23 (24.5%) |
|
|
Disease Type |
|||
|
Luminal A |
128 (63.4%) |
51 (54.3%) |
0.353 |
|
Luminal B |
9 (4.5%) |
7 (7.5%) |
|
|
Her-2/Neu |
5 (2.5%) |
2 (2.1%) |
|
|
Basal |
16 (7.9%) |
11 (3.7%) |
|
|
DCIS |
40 (19.8%) |
18 (6.1%) |
|
|
Unable to classify |
4 (2.0%) |
5 (5.3%) |
|
|
LVSI (Invasive Only) |
0.591 |
||
|
Present |
10 (4.9%) |
6 (8.1%) |
|
|
Absent |
152 (74.5%) |
70 (91.9%) |
|
|
LCIS |
0.011* |
||
|
Present |
15 (7.4%) |
17 (18.1%) |
|
|
Absent |
187 (92.6%) |
77 (81.9%) |
|
|
EIC (Invasive Only) |
0.688 |
||
|
Present |
4 (2.5%) |
3 (3.9%) |
|
|
Absent |
148 (91.4%) |
73 (96.1%) |
|
|
Unknown |
10 (6.2%) |
0 (0%) |
|
|
Endocrine Therapy (Invasive Only) |
0.182 |
||
|
Given |
127 (78.4%) |
50 (65.8%) |
|
|
Not Given |
34 (21.0%) |
21 (27.6%) |
|
|
Unknown |
1 (0.6%) |
5 (6.6%) |
|
|
Endocrine Therapy (DCIS Only) |
0.756 |
||
|
Given |
29 (72.5%) |
14 (77.8%) |
|
|
Not Given |
11 (27.5%) |
4 (22.2%) |
|
|
Unknown |
0 (0%) |
0 (0%) |
|
|
Cytotoxic Chemotherapy (Invasive Only) |
0.102 |
||
|
Given |
35 (21.6%) |
23 (30.3%) |
|
|
Not Given |
127 (78.4%) |
49 (64.5%) |
|
|
Unknown |
0 (0%) |
4 (5.3%) |
|
|
|
|||
|
* Statistically significant |
|||
|
Ferraro et al. Radiation Oncology 2012 7:53 doi:10.1186/1748-717X-7-53 |
|||
